2ATScommittee on proficiency standards for clinical pulmonaryfunction Laboratories. ATS statement: guidelines for the six minutewalk test. Am J Respir Crit Care Med,2002,166: 111.
4Davie NJ,Schermuly RT,Weissmann N,et al. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies[J]. Eur J Clin Invest, 2009,39 (Suppl 2) : 38-49.
5Sauvageau S,Thorin E, Villeneuve L, et al. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels[J]. Pulm Pharmacol Ther,2009,22(4):311-317.
6Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2009,54 (Suppl 1):20-31.
8Choi J, Husain M.Calmodulin-mediated cell cycle regulation: new mechanisms for old observations[J]. Cell Cycle, 2006,5 (19) : 2183-2186.
9Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension[J].J Am Coll Cardiol,2004,43(Suppl 12) : 13-24.
10Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cetls[J]. Curr Vasc Pharmacol, 2007,5 (1) : 45-52.
